Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

A 38-year-old man using minoxidil, tretinoin, and microneedling for hair loss is considering adding finasteride to his regimen. He is concerned about potential effects on beard growth but seeks advice on whether to add finasteride now or wait.

The user updated their hair loss treatment to include daily dutasteride, oral minoxidil, topical dutasteride with minoxidil and tretinoin, and RU58841. Commenters feel the extensive treatment is unnecessary for the user's level of hair loss.

Hair loss discussion mentions Minoxidil, Finasteride, and RU58841. User seeks opinions on Redensyl for hair regrowth and safety.

A 26-year-old discusses hair loss treatment using oral finasteride microdosing, topical minoxidil with tretinoin, and dermastamping every 10 days. They started experiencing hair loss at 19 and have been using these treatments for 8 months.

A user reported noticeable hair regrowth using a 272 diode red light therapy hat over 11 months without Minoxidil or Finasteride. Opinions vary on its effectiveness compared to traditional treatments, with some suggesting combining therapies for better results.

Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.

Hair loss treatments, such as minoxidil and finasteride, being replaced by verteporfin, with humorous responses.

A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.

The user has been using finasteride 1.2mg daily, topical minoxidil 1ml daily, tretinoin with topical minoxidil 1ml every other day, and a 1.5mm derma roller every two weeks for 8 months to treat hair loss. The user has posted progress pictures over time.

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

The user is concerned about post-hair transplant care, specifically regarding the use of a bandana, minoxidil, and tretinoin. They are advised to consider finasteride and possibly adjust the minoxidil dosage.

Hair loss discussion includes PRP procedures. Some say it's not worth the money.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

The conversation is about the potential of the RCH-01/Replicel hair loss treatment and its lack of updates since 2013, with the user expressing hope for its success and considering using Minoxidil, finasteride, and dermarolling in the meantime. Other treatments mentioned as promising are Breezula and Tsuji.

The post discusses the use of latanoprost foam for hair growth, with the user expressing concerns about its efficiency and safety. The user is currently using topical dutasteride, which maintains their hair but doesn't promote regrowth, and is seeking a product that doesn't affect hormone levels.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

User on finasteride and redensyl serum sees progress, considers switching to minoxidil and topical finasteride mix. Another user claims topical mix is more effective than oral finasteride and has no side effects.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The routine involves using minoxidil, dermapen, and tretinoin for hair loss, with minoxidil applied daily and tretinoin used on alternate days. It is suggested to avoid using tretinoin and dermapen on the same day to prevent irritation.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

The conversation discusses obtaining an online EU prescription for Bimatoprost/Lumigan for hair loss without an in-person doctor visit. The user is seeking alternatives to physical consultations for this treatment.

The user is considering adjusting tretinoin strength to enhance minoxidil effectiveness, questioning whether to use 0.025% or 0.01% instead of 0.05% due to increased hair shedding. They have been using finasteride, minoxidil, and Nizoral, and are contemplating reintroducing microneedling.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.